We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Aegon Ltd | EU:AGN | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.024 | 0.41% | 5.882 | 5.85 | 5.886 | 5.94 | 5.854 | 5.882 | 4,842,031 | 16:40:00 |
International stocks trading in New York closed mixed Friday.
The BNY Mellon index of American depositary receipts improved 0.38% to 125.07. The European index increased 0.41% to 126.22, and the Asian index rose 0.51% to 130.11. Meanwhile, the Latin American index fell 0.55% to 156.26 and the emerging-markets index eased 0.23% to 204.82. Galapagos NV (GLPG, GLPG.AE) and Abengoa SA (ABGB, ABG.MC) were among the companies whose ADRs traded actively.
ADRs of Abengoa fell 8% to $4.99 on Friday after the financially strapped Spanish renewable-energy company set a date for a special meeting of shareholders to vote on a proposed overhaul, including a 650-million-euro capital increase, asset disposals and new corporate-governance measures. The meeting is scheduled for Oct. 10, or Oct. 11 if the required quorum is not met Oct. 10.
Dutch insurance firm Aegon NV (AEG, AGN.AE) said Friday it is buying Mercer HR Service LLC's U.S. defined contribution administration book of business in a deal that adds $71 billion to its assets under administration. Aegon didn't disclose how much it was paying for the business. The deal is expected to close in the fourth quarter. ADRs rose 2.5% to $5.75.
ADRs of Galapagos NV (GLPG, GLPG.AE) tumbled 27% to $44.60 on Friday after AbbVie Inc. decided not to license Galapagos's rheumatoid-arthritis drug, filgotinib, and focus instead on its own, ABT-494.
-30 -
(MORE TO FOLLOW) Dow Jones Newswires
September 25, 2015 17:51 ET (21:51 GMT)
Copyright (c) 2015 Dow Jones & Company, Inc.
1 Year Aegon Chart |
1 Month Aegon Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions